Halobetasol Propionate
A very high-potency topical corticosteroid used to treat inflammatory and pruritic manifestations of corticosteroid-responsive skin conditions such as psoriasis and eczema. It reduces inflammation and itching by suppressing the local immune response in the skin. Due to its potency, treatment duration and body surface area should be limited to minimize systemic absorption.
Peso molecular
485,0000 g/mol
LogP
3,70
TPSA
80,70 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
InChI
InChI=1S/C25H31ClF2O5/c1-5-21(32)33-25(20(31)12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15-,16-,18-,19-,22-,23-,24-,25-/m0/s1
Molecular Formula
C25H31ClF2O5
HBD / HBA
1 / 7
Enlaces Rotables
5
Átomos Pesados
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A very high-potency topical corticosteroid used to treat inflammatory and pruritic manifestations of corticosteroid-responsive skin conditions such as psoriasis and eczema. It reduces inflammation and itching by suppressing the local immune response in the skin. Due to its potency, treatment duration and body surface area should be limited to minimize systemic absorption.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Halobetasol Propionate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200908. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6918178. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="halobetasol-propionate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/halobetasol-propionate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/halobetasol-propionate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/halobetasol-propionate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="halobetasol-propionate"></drugfyi-drug>